期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
yrdC靶向RNA干扰抑制BGC-823细胞裸鼠体内成瘤的实验研究 被引量:1
1
作者 朱宏亮 毕建威 +3 位作者 黄盛东 方国恩 袁扬 杨庭松 《江西医学院学报》 2009年第11期1-5,共5页
目的检测胃癌组织及癌旁正常组织中的yrdC的mRNA、蛋白表达。构建表达yrdC靶向RNA干扰的重组腺病毒,转染人胃癌细胞株BGC-823,检测干扰后BGC-823细胞yrdC蛋白水平变化,转染后细胞移植裸鼠体内成瘤,观察yrdC沉默后移植瘤生长的变化。方... 目的检测胃癌组织及癌旁正常组织中的yrdC的mRNA、蛋白表达。构建表达yrdC靶向RNA干扰的重组腺病毒,转染人胃癌细胞株BGC-823,检测干扰后BGC-823细胞yrdC蛋白水平变化,转染后细胞移植裸鼠体内成瘤,观察yrdC沉默后移植瘤生长的变化。方法采用逆转录-聚合酶链反应(RT-PCR)和Western blot法,检测7例胃癌组织及癌旁正常组织中的yrdC的mRNA、蛋白表达。构建表达针对人yrdC的si RNA的重组腺病毒,重组腺病毒Ad-shyrdC转染BGC-823细胞,Western blot检测干扰后BGC-823细胞yrdC蛋白水平变化。裸鼠分3组,分别皮下移植转染Ad-shyrdC、空病毒Ad-Null及未转染的BGC-823细胞(1×107/只),5周后检测裸鼠肿瘤的体积及质量,肿瘤HE染色及yrdC、PCNA、TUNEL免疫组化染色,观察各组yrdC蛋白表达、细胞增殖能力及细胞凋亡的变化。结果胃癌组织中yrdC mRNA及蛋白表达量均比癌旁组织增高。成功构建表达抑制yrdC基因的重组腺病毒Ad-shyrdC,腺病毒介导的yrdC靶向RNA干扰能特异性抑制BGC-823中yrdC蛋白的表达,Ad-shyrdC组肿瘤细胞yrdC蛋白水平明显下降。转染BGC-823细胞后移植裸鼠体内,5周后成瘤体积及质量较Ad-Null组及PBS对照组明显减小(P<0.05);yrdC蛋白表达减少,PCNA染色提示肿瘤细胞增殖活性受抑,TUNEL染色显示凋亡明显增多(P<0.01)。结论腺病毒介导的RNA干扰能有效抑制BGC-823细胞裸鼠体内成瘤,yrdC基因有可能成为胃癌基因治疗的靶点。 展开更多
关键词 yrdc基因 RNA干扰 胃癌细胞 动物 实验 裸鼠
暂未订购
Expression of human yrdC gene promotes proliferation of gastric carcinoma cells 被引量:1
2
作者 Tingsong Yang Xiaojun Shen +6 位作者 Jianwei Bi Shengdong Huang Guo Wei Hongliang Zhu Xiaojun Tang Yang Yuan Dejun Gong 《The Chinese-German Journal of Clinical Oncology》 CAS 2009年第8期433-437,共5页
Objective: The aim of the research was to study the function of human yrdC gene in the gastric carcinoma cells. Methods: Human yrdC gene was isolated from human spleen tissue by RT-PCR. Anti-human yrdC monoclonal an... Objective: The aim of the research was to study the function of human yrdC gene in the gastric carcinoma cells. Methods: Human yrdC gene was isolated from human spleen tissue by RT-PCR. Anti-human yrdC monoclonal antibody was prepared by hybridoma cell technique. Recombinant adenovirus Ad.yrdC carrying yrdC gene was constructed by using the AdEasy adenoviral vector system. Recombinant adenovirus Ad.yrdCshRNA mediated yrdCshRNA was prepared by RNA interference technology. Gastric adenocarcinoma BGC-823 cells of moderate differentiation were transfected and absorbance of the transfected cells was calculated at 490 nm by methyl thiazolyl tetrazolium (MTT) method. Results: A value of the transfected Ad.yrdC group was significantly greater than that of the non-transfected and transfected Ad.Null groups, and A value of Ad.yrdCshRNA group was significantly lower than that of the non-transfected and transfected Ad.Null groups. Conclusion: Expression of yrdC gene has a function of promoting the proliferation of gastric carcinoma cells. 展开更多
关键词 human yrdc gene gastric carcinoma monoclonal antibody recombinant adenovirus
在线阅读 下载PDF
结直肠癌中YRDC表达水平及其预后价值
3
作者 周信阳 蓝旭丽 +1 位作者 雷桃英 钟发明 《全科医学临床与教育》 2024年第1期11-14,F0003,共5页
目的 明确YRDC基因是否在结直肠癌中具有原癌基因的表达特性,其与患者临床病例资料的相关性及其对远期预后的影响。方法 选择确诊为结直肠癌的156例患者,采用免疫组织化学法检测其癌组织及癌旁组织样本中的YRDC的表达水平。分析患者的... 目的 明确YRDC基因是否在结直肠癌中具有原癌基因的表达特性,其与患者临床病例资料的相关性及其对远期预后的影响。方法 选择确诊为结直肠癌的156例患者,采用免疫组织化学法检测其癌组织及癌旁组织样本中的YRDC的表达水平。分析患者的临床参数与YRDC表达的相关性。并采用Kaplan-Meier法评估绘制患者的生存曲线,用COX模型对结直肠癌患者的预后进行多因素分析。结果 YRDC蛋白在结直肠癌组织中的表达明显高于癌旁组织,差异有统计学意义(χ~2=143.22,P<0.05)。YRDC高表达患者的生存期明显短于低表达患者,1年存活率、末次随访存活率均低于低表达患者,复发转移率高于低表达患者,差异均有统计学意义(t=40.13,χ~2分别=6.91、7.81、8.12,P均<0.05)。COX回归分析显示,远处转移、癌胚抗原、YRDC表达是结直肠癌患者生存结局的独立影响因素(OR分别=3.13、34.75、2.22,P均<0.05)。结论 YRDC的高水平表达往往预示着不良的预后,YRDC基因可能成为判断结直肠癌患者预后的潜在生物标志物,这有助于进一步找到结直肠癌分子治疗的作用靶点。 展开更多
关键词 结直肠癌 yrdc 表达 预后
暂未订购
RNA Structural Dynamics Modulate EGFR-TKI Resistance Through Controlling YRDC Translation in NSCLC Cells 被引量:1
4
作者 Boyang Shi Ke An +6 位作者 Yueqin Wang Yuhan Fei Caixia Guo Qiangfeng Cliff Zhang Yun-Gui Yang Xin Tian Quancheng Kan 《Genomics, Proteomics & Bioinformatics》 SCIE CAS CSCD 2023年第4期850-865,共16页
Epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)positively affect the initial control of non-small cell lung cancer(NSCLC).Rapidly acquired resistance to EGFR-TKIs is a major hurdle in successful... Epidermal growth factor receptor-tyrosine kinase inhibitors(EGFR-TKIs)positively affect the initial control of non-small cell lung cancer(NSCLC).Rapidly acquired resistance to EGFR-TKIs is a major hurdle in successful treatment.However,the mechanisms that control the resistance of EGFR-TKIs remain largely unknown.RNA structures have widespread and crucial functions in many biological regulations;however,the functions of RNA structures in regulating cancer drug resistance remain unclear.Here,the psoralen analysis of RNA interactions and structures(PARIS)method is used to establish the higher-order RNA structure maps of EGFRTKIs-resistant and-sensitive cells of NSCLC.Our results show that RNA structural regions are enriched in untranslated regions(UTRs)and correlate with translation efficiency(TE).Moreover,yrdC N6-threonylcarbamoyltransferase domain containing(YRDC)promotes resistance to EGFR-TKIs.RNA structure formation in YRDC 30 UTR suppresses embryonic lethal abnormal vision-like 1(ELAVL1)binding,leading to EGFR-TKI sensitivity by impairing YRDC translation.A potential therapeutic strategy for cancer treatment is provided using antisense oligonucleotide(ASO)to perturb the interaction between RNA and protein.Our study reveals an unprecedented mechanism through which the RNA structure switch modulates EGFR-TKI resistance by controlling YRDC mRNA translation in an ELAVL1-dependent manner. 展开更多
关键词 RNA structure EGFR-TKI resistance Non-small cell lung cancer yrdc ELAVL1
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部